Spots Global Cancer Trial Database for Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer
Official Title: Phase II Study of Cetuximab Plus P-HDFL(Cisplatin and Weekly 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin)for the First-line Treatment of Advanced Gastric Cancer
Study ID: NCT00275951
Conditions
Interventions
Study Description
Brief Summary: The investigators have initial evidence that the combination of cetuximab and cisplatin-HDFL may further improve the efficacy of the cisplatin-HDFL combination chemotherapy.
Detailed Description: The clinical efficacy (confirmed objective response rates, progression-free survival, overall survival), and treatment-related toxicities of this novel regimen will be examined as the first-line treatment in patients with nonresectable or recurrent/metastatic gastric cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Oncology, National Taiwan University Hospital, Taipei, , Taiwan
Contact Details
Name: Ann-Lii Cheng, M.D., Ph.D.
Affiliation: Department of Oncology, National Taiwan University Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
